IOVA Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, May 21, 2025 /PRNewswire/ -- Biotechnology firm Iovance Biotherapeutics, Inc. (NASSAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v. Iovance Biotherapeutics, Inc., et al., centers on statements made between May 9, 2024, and May 8, 2025, ...